Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 732 - 732

Published: Feb. 21, 2025

In the era of precision medicine, mounting evidence suggests that time therapy administration, or chronotherapy, has a great impact on treatment outcomes. Chronotherapy involves planning timing by considering circadian rhythms, which are 24 h oscillations in behavior and physiology driven synchronized molecular clocks throughout body. The value chronotherapy cancer is currently under investigation, notably effects efficacy side effects. Immune checkpoint inhibitor (ICI) promising treatment. However, many patients still experience disease progression need to stop early due There accumulating day at ICI administered can have substantial effect efficacy. Thus, it important investigate intersections this review, we provide brief overview rhythms context immunity cancer. Additionally, outline current applications for We synthesize 29 studies conducted date examine time-of-day administration therapy, its associated effects, sex differences both also discuss potential mechanisms underlying these observed results. Finally, highlight challenges area future directions research, including chronotherapeutic personalized medicine approach tailors individual patients’ rhythms.

Language: Английский

Immune-Related Adverse Events in a Patient Treated with Pembrolizumab: A Case Report from the Point of View of a Geriatrician

Geriatrics, Journal Year: 2024, Volume and Issue: 9(6), P. 160 - 160

Published: Dec. 11, 2024

We report the case of a 78-year-old female patient who received palliative immunotherapy with pembrolizumab and lenvatinib as treatment pulmonary osseous metastatic endometrial carcinoma. Under this therapy, developed dysphagia, thyroiditis hypothyroidism, myositis, myocarditis, which required, due to third-degree AV block, installation pacemaker. The high-dose cortisone thyroid hormone substitution, pyridostigmine for symptom control. With we saw significant but not complete regression symptoms. Ultimately, could discharge home an outpatient treatment. is followed by discussion management immune-related adverse events (irAEs) during therapy from geriatric perspective. Elderly patients on require close monitoring irAEs, can present atypically or without symptoms may be fatal. Non-invasive diagnostics minimizing hospital stays are essential preserve fitness vulnerable population.

Language: Английский